Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

PCSK9 and Lipid Metabolism: Genetic Variants, Current Therapies, and Cardiovascular Outcomes.

Cardiovascular drugs and therapy - 1 Dec 2025

Grejtakova Daniela, Boronova Iveta, Bernasovska Jarmila, Bellosta Stefano

Abstract excerpt

Proprotein convertase subtilisin/kexin type 9 (PCSK9) plays a crucial role in the modulation of lipid metabolism as a critical negative regulator of hepatic low-density lipoprotein receptor (LDLR) levels and circulating low-density lipoprotein (LDL) clearance. Numerous gain-of-function (GOF) mutations in PCSK9 have been identified as causing familial hypercholesterolemia (FH) by reducing LDLR levels, and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anticholesteremic Agents
Share to Cardiovascular Diseases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to FH gene

Share to PCSK9 gene

Share to Genetic Variation

Share to Lipid Metabolism

Share to Proprotein Convertase 9

Share to Receptors, LDL

Source

Open in PubMed Open full text

Identifiers

PMID: 38907775
DOI: 10.1007/s10557-024-07599-5
PMCID: PMC12717104

Genes

PCSK9
LDLR
FH

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

PCSK9 and Lipid Metabolism: Genetic Variants, Current Therapies, and Cardiovascular Outcomes.PMID 38907775Read ↗

Clinical aspects of PCSK9.Semantic proximity Read ↗

PCSK9 Variants in Familial Hypercholesterolemia: A Comprehensive SynopsisSemantic proximity Read ↗

PCSK9 gene mutations and low-density lipoprotein cholesterol.Semantic proximity Read ↗

Mutations and polymorphisms in the proprotein convertase subtilisin kexin 9 (PCSK9) gene in cholesterol metabolism and disease.Semantic proximity Read ↗

PCSK9: a key modulator of cardiovascular health.Semantic proximity Read ↗

The next generation of novel low-density lipoprotein cholesterol-lowering agents: proprotein convertase subtilisin/kexin 9 inhibitors.Semantic proximity Read ↗

The influence of PCSK9 polymorphisms on serum low-density lipoprotein cholesterol and risk of atherosclerosis.Semantic proximity Read ↗

LDL-cholesterol and PCSK9 in patients with familial hypercholesterolemia: influence of PCSK9 variants under lipid-lowering therapy.Semantic proximity Read ↗

Genetic Regulation of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Plasma Levels and Its Impact on Atherosclerotic Vascular Disease Phenotypes.Semantic proximity Read ↗

The role of proprotein convertase subtilisin/kexin type 9 in hyperlipidemia: focus on therapeutic implications.Semantic proximity Read ↗

Molecular biology of PCSK9: its role in LDL metabolism.Semantic proximity Read ↗

PCSK9 inhibitors: the next frontier in low-density lipoprotein lowering.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.